

MAT Waiver Training

ONLINE | Completed Prior + LIVE | 9am-1:30pm

Friday April 27th, 2018 at
the Hilton Garden Inn

Bend Training

Click to Register

Tuition: No Cost

For more information and to register, visit
<https://matcotraining.eventbrite.com>

What is MAT Waiver Training?

The PCSS-MAT Half and Half Medication Assisted Treatment (MAT) waiver training course provides an overview of the FDA-approved medications – buprenorphine, naltrexone, and methadone – prescribed for the treatment of opioid use disorder (OUD). This course provides the required eight-hour training to prescribe buprenorphine in office-based settings for the treatment of OUD. The course provides an overview of prevention, identification, and treatment of substance use disorders emphasizing OUD. Currently, physicians who have completed the eight-hour course are eligible to apply for the waiver to prescribe buprenorphine. Residents may take the course and apply for their waiver when they receive their DEA license. Physicians Assistants (PAs) and Advanced Practice Registered Nurses (APRNs) are also encouraged to take the course.

Half and Half Course

This course will be provided in a “Half and Half” format which means the first half of the course is taken on-line and the second half is completed live (in-person). The first half (on-line course) must be completed before the live course on April 27th.

After registering for the course at <https://matcotraining.eventbrite.com>, participants will be emailed instructions on the first half of the course. Those who have successfully completed the course (both on-line and live) are eligible to apply to SAMHSA to obtain a waiver to prescribe buprenorphine. PCSS-MAT urges all participants who complete the course to submit a Notice of Intent Form to SAMHSA, available on-line and provided by email following the training.

PCSS-MAT has a comprehensive library of materials available at no cost, created to give providers confidence in preventing and treating these medical disorders. PCSS-MAT also provides a no-cost clinical coaching/mentoring program to help primary care providers in their ability to address these concerns.

Accreditation

CME Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of OHSU and AAAP. OHSU is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

OHSU School of Medicine designates this (second “half” of the course) live activity for a maximum of **4.5 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Physician Participation in the Learning Process

Physicians will only be awarded **4.5 AMA PRA Category 1 Credits™** for completing the “second” half of the training. To obtain a buprenorphine training certificate of completion you must complete BOTH halves of the training and receive a minimum cumulative score of 75% on the examination.

Disclosure of Support

Funding for this initiative was made possible by the SAMHSA-funded American Association of Addiction Psychiatry’s Provider Clinical Support Service (PCSS) for Medication Assisted Treatment. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Partial funding for this program comes from SAMHSA to the Oregon

Health Authority to expand MAT capacity across Oregon. Additional funding is also provided through the Central Oregon Health Council and OHSU.

